By YI-LING LIU/DECEMBER 3, 2018
Photos by ELKE SCHOLIERS FOR STAT
SHANGHAI — Harbour BioMed opened its first office in a Shanghai industrial park in 2016, with a team of eight people. Just two years later, it has become a global biotech company, with offices in Boston and Rotterdam, Netherlands, and more than 150 employees. Here in China, they’re spread among three new labs, and a new office is under construction in walking distance to a cancer hospital. Even so, in Harbour’s original lab, scientists work shoulder to shoulder, sharing limited bench space.
That sort of explosive growth is not all that remarkable here: This is China’s Kendall Square, the epicenter of the country’s biotech industry, where scaffolding sprouts like weeds.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.